ConquerX develops a minimally invasive blood test that can screen and detect different types of cancer based on cutting-edge molecular sensor technology.

Panther Therapeutics has developed a drug delivery platform for local delivery of small molecules, macromolecules, and biologics to GI cancers. Our lead indication is local delivery of chemotherapeutics for pancreatic cancer.

Suono Bio has developed breakthrough technology, the “SuonoCalm” that enables ultra-rapid delivery of therapeutics across tissues, including the gastrointestinal (GI) tract. SuonoCalm, which delivers small and large molecules locally and systemically can be used for the treatment of inflammatory bowel disease (IBD), cancer, and infectious GI conditions, and be applied to a broad set of conditions outside of the GI tract. Our innovative technology, expertise in drug delivery and clinical gastroenterology, and extensive intellectual property positions Suono Bio to transform GI-based drug delivery.

Angiex is creating an antibody-drug conjugate therapy for cancer against a vascular target. Angiex's ADC has achieved long-lasting regressions from a single treatment in numerous mouse xenograft and syngeneic tumor models.

Adecto Pharmaceuticals is an early-stage therapeutics company developing innovative therapies for highly aggressive cancers. The first product in our pipeline is an antibody-based therapy for triple-negative breast cancer.

Novopyxis' lead drug candidate is shown to activate a key receptor to treat cardiovascular disease by improving cardiac function, vascular elasticity and reducing cardiac cell death and fibrosis.

BiomaRx is an oncology-focused startup in Cambridge, MA, focused on making pancreatic cancer a treatable condition. We have identified a highly promising test for early-stage diagnosis and a potential non-invasive screen for pancreatic cancer. Spun out of Harvard Medical School and Beth Israel Deaconess Medical Center, BiomaRx uses a proprietary systems biology engine to identify next-gen diagnostic biomarkers and therapeutic targets for first-in class pancreatic cancer drugs.

Canomiks is using sophisticated genomics and systems biology approaches to develop herbal formulations that counteract gene expression signatures associated with chronic conditions. Using their proprietary GeneTune® bioinformatics platform technology, Canomiks has designed multi-herb formulations targeted at modifying the genomic signatures for Type2Diabetes, Inflammatory Bowel Disease (IBD) and Arthritis.